Overall world revenue for the Cell and Gene Therapy Cold Chain Logistics Market: In terms of value the market will surpass US$2.16 billion in 2025, the work calculates. The publisher predicts strong revenue growth through to 2035. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
The Cell & Gene Therapy Cold Chain Logistics Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Given their temperature sensitivity and complex storage needs, cell and gene therapies rely heavily on sophisticated cold chain logistics systems. These therapies often need to be transported and stored at ultra-low or cryogenic temperatures, requiring specialised packaging, real-time temperature monitoring, and localised storage infrastructure near treatment centres. In response, logistics providers are investing in innovative solutions such as smart cryogenic containers, decentralised cold chain hubs, and integrated digital platforms for end-to-end traceability. As more therapies gain regulatory approval and enter the market, these enhanced logistics capabilities are becoming critical to expanding patient access, ensuring that transformative treatments can be delivered safely and efficiently across diverse geographic regions.
These infrastructure limitations also hinder broader healthcare delivery, including the preservation and distribution of vaccines, which share similar cold chain requirements. For example, a study in Ethiopia's East Gojam zone (Amhara region) highlighted major gaps in cold chain readiness: only 76.7% of health facilities had functional refrigerators, 35% had backup generators, and less than half had vehicles available to support vaccine transport during equipment or power outages. Compounding the issue, just 38.3% of healthcare workers were found to have adequate knowledge of cold chain management. These findings underscore the urgent need for targeted investments in infrastructure, training, and innovation to strengthen cold chain logistics in underserved regions ensuring equitable access to advanced therapies and improving global health outcomes.
Moreover, countries impacted by US tariffs may retaliate with their own trade restrictions, further fragmenting the cold chain ecosystem. For global biopharmaceutical companies, this could result in a re-evaluation of manufacturing and distribution hubs, with a shift toward more localised supply chains to minimise tariff exposure. Smaller CGT firms, already burdened by high production and regulatory costs, may struggle to absorb tariff-induced price increases, leading to delays in commercialisation or limited patient access. In the long term, such trade tensions could incentivise innovation in local cold chain infrastructure and strategic alliances, but they would also reduce global interoperability and increase barriers to international collaboration in advanced therapies.
In addition to cost and supply chain disruptions, US trade tariffs can also hinder the global scalability of emerging cell and gene therapies. Many CGT developers rely on specialised equipment, reagents, or packaging materials sourced from international suppliers, and tariffs can lead to bottlenecks in procurement or force reliance on lower-quality alternatives. This not only affects production timelines but also raises concerns about product stability and compliance with Good Distribution Practices (GDP). Furthermore, tariffs may discourage global logistics companies from investing in cross-border infrastructure improvements, especially in emerging markets, slowing the development of a globally harmonised cold chain network. Overall, such trade barriers can delay patient access to life-saving therapies and increase inequality in treatment availability between developed and developing regions.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:
The Cell & Gene Therapy Cold Chain Logistics Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
High Prevalence of Cancer and Genetic Disorders Driving the Market Growth
Cancer remains one of the leading causes of mortality and morbidity globally, with its rising prevalence fuelled by factors such as sedentary lifestyles, increased alcohol and tobacco use, and limited awareness in underdeveloped regions. Alongside this, the burden of rare diseases is growing rapidly. According to a WHO report dated 24 May 2025, over 300 million people worldwide approximately 1 in every 17 are living with a rare disease. This surge in complex, often life-threatening conditions is significantly boosting the demand for advanced cell and gene therapies, many of which are tailored to individual patients and require precise handling to ensure efficacy.Given their temperature sensitivity and complex storage needs, cell and gene therapies rely heavily on sophisticated cold chain logistics systems. These therapies often need to be transported and stored at ultra-low or cryogenic temperatures, requiring specialised packaging, real-time temperature monitoring, and localised storage infrastructure near treatment centres. In response, logistics providers are investing in innovative solutions such as smart cryogenic containers, decentralised cold chain hubs, and integrated digital platforms for end-to-end traceability. As more therapies gain regulatory approval and enter the market, these enhanced logistics capabilities are becoming critical to expanding patient access, ensuring that transformative treatments can be delivered safely and efficiently across diverse geographic regions.
Absence of Adequate Infrastructure for Cold Chain Logistics in Developing Nations is Hindering the Market Growth
The lack of robust cold chain infrastructure in developing countries and remote regions presents significant barriers to the effective distribution of cell and gene therapies, which require stringent temperature control to maintain their viability. A critical issue is the shortage of reliable refrigeration systems, which are vital for safeguarding the integrity of temperature-sensitive biologics during storage and transport. In areas where electricity supply is unstable or inconsistent, maintaining the required cold chain conditions becomes nearly impossible, increasing the risk of product degradation. To overcome this, innovative solutions are emerging such as those offered by Sure Chill, whose alternative cooling technology can maintain stable temperatures without continuous power supply, making it ideal for use in electricity-deficient settings.These infrastructure limitations also hinder broader healthcare delivery, including the preservation and distribution of vaccines, which share similar cold chain requirements. For example, a study in Ethiopia's East Gojam zone (Amhara region) highlighted major gaps in cold chain readiness: only 76.7% of health facilities had functional refrigerators, 35% had backup generators, and less than half had vehicles available to support vaccine transport during equipment or power outages. Compounding the issue, just 38.3% of healthcare workers were found to have adequate knowledge of cold chain management. These findings underscore the urgent need for targeted investments in infrastructure, training, and innovation to strengthen cold chain logistics in underserved regions ensuring equitable access to advanced therapies and improving global health outcomes.
What would be the Impact of US Trade Tariffs on the Global Cell and Gene Therapy Cold Chain Logistics Market?
The imposition of the U.S. trade tariffs can significantly disrupt the global cell and gene therapy (CGT) cold chain logistics market, which relies heavily on international coordination and seamless cross-border movement of temperature-sensitive materials. Tariffs on critical components such as cryogenic containers, temperature-monitoring devices, or even specific raw materials used in therapy manufacturing could lead to higher costs across the supply chain. For logistics providers, this would mean increased operational expenses, potential delays due to customs clearance complications, and the need to reconfigure sourcing strategies. These changes could compromise the time-sensitive nature of CGT delivery, affecting therapy efficacy and regulatory compliance.Moreover, countries impacted by US tariffs may retaliate with their own trade restrictions, further fragmenting the cold chain ecosystem. For global biopharmaceutical companies, this could result in a re-evaluation of manufacturing and distribution hubs, with a shift toward more localised supply chains to minimise tariff exposure. Smaller CGT firms, already burdened by high production and regulatory costs, may struggle to absorb tariff-induced price increases, leading to delays in commercialisation or limited patient access. In the long term, such trade tensions could incentivise innovation in local cold chain infrastructure and strategic alliances, but they would also reduce global interoperability and increase barriers to international collaboration in advanced therapies.
In addition to cost and supply chain disruptions, US trade tariffs can also hinder the global scalability of emerging cell and gene therapies. Many CGT developers rely on specialised equipment, reagents, or packaging materials sourced from international suppliers, and tariffs can lead to bottlenecks in procurement or force reliance on lower-quality alternatives. This not only affects production timelines but also raises concerns about product stability and compliance with Good Distribution Practices (GDP). Furthermore, tariffs may discourage global logistics companies from investing in cross-border infrastructure improvements, especially in emerging markets, slowing the development of a globally harmonised cold chain network. Overall, such trade barriers can delay patient access to life-saving therapies and increase inequality in treatment availability between developed and developing regions.
Key Questions Answered
- How is the cell and gene therapy cold chain logistics market evolving?
- What is driving and restraining the cell and gene therapy cold chain logistics market?
- How will each cell and gene therapy cold chain logistics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
- How will the market shares for each cell and gene therapy cold chain logistics submarket develop from 2025 to 2035?
- What will be the main driver for the overall market from 2025 to 2035?
- Will leading cell and gene therapy cold chain logistics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
- Who are the leading players and what are their prospects over the forecast period?
- What are the cell and gene therapy cold chain logistics projects for these leading companies?
- How will the industry evolve during the period between 2025 and 2035? What are the implications of cell and gene therapy cold chain logistics projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the cell and gene therapy cold chain logistics market?
- Where is the cell and gene therapy cold chain logistics market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the cell and gene therapy cold chain logistics market today, and over the next 10 years:
- This 422-page report provides 176 tables and 204 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2035 and other analysis reveal commercial prospects
- In addition to revenue forecasting to 2035, the new study provides you with recent results, growth rates, and market shares.
- You will find original analysis, with business outlooks and developments.
- Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising cell and gene therapy cold chain logistics prices and recent developments.
Segments Covered in the Report
Component
- Cryogenic Shippers
- Cryogenic Storage Freezers
- Ultra-Low Freezers
- Cold Chain Management Systems
- Shipment and Storage Medium
- Cryogenic Packout Kits
- Others
Services
- Transportation
- Storage
- Packaging
Mode of Transport
- Air Transport
- Ground Transport
- Water Transport
Holding Temperature Range
- Cryogenic
- Refrigerated
- Ambient
- Others
End-users
- Biopharmaceutical and Biotechnology Companies
- Academic & Research Institutes
- Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Switzerland
- Belgium
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Singapore
- Malaysia
- Thailand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Leading companies profiled in the report
- A.P. M√∏ller - Maersk
- Arvato SE
- Atelerix Ltd.
- BioLife Solutions Inc.
- BioStor Sytems Inc.
- Cardinal Health
- Catalent Inc.
- Cencora, Inc.
- CEVA Logistics
- CryoPort Inc.
- DB Schenker
- Delhivery Limited
- DHL
- FedEx
- Marken (a UPS Company)
- MasterControl Solutions, Inc.
- Modality Solutions
- NMDP BioTherapies
- Nordic Cold Chain Solutions
- Polar Express Transportation
- sedApta s.r.l.
- Thermo Fisher Scientific Inc.
- TrakCel
- Yourway
- YUSEN LOGISTICS
How will the Cell and Gene Therapy Cold Chain Logistics Market report help you?
In summary, the 420+ page report provides you with the following knowledge:- Revenue forecasts to 2035 for Cell and Gene Therapy Cold Chain Logistics Market, with forecasts for component, services, mode of transport, holding temperature range, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2035 for five regional and 21 key national markets - See forecasts for the Cell and Gene Therapy Cold Chain Logistics Market in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 25 of the major companies involved in the Cell and Gene Therapy Cold Chain Logistics Market.
Table of Contents
1 Report Overview
3 Market Overview
4 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Components
5 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Services
6 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Mode of Transport
7 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Holding Temperature
8 Cell and Gene Therapy Cold Chain Logistics Market Analysis by End-users
9 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Region
10 North America Cell and Gene Therapy Cold Chain Logistics Market Analysis
11 Europe Cell and Gene Therapy Cold Chain Logistics Market Analysis
12 Asia Cell and Gene Therapy Cold Chain Logistics Market Analysis
13 Latin America Cell and Gene Therapy Cold Chain Logistics Market Analysis
14 MEA Cell and Gene Therapy Cold Chain Logistics Market Analysis
15 Company Profiles
16 Conclusion and Recommendations
List of Tables
List of Figures
Companies Mentioned
- A.P. M√∏ller – Maersk
- Arvato SE
- Atelerix Ltd.
- BioLife Solutions Inc.
- BioStor Sytems Inc.
- Cardinal Health
- Catalent Inc.
- Cencora, Inc.
- CEVA Logistics
- CryoPort Inc.
- DB Schenker
- Delhivery Limited
- DHL
- FedEx
- Marken (a UPS Company)
- MasterControl Solutions, Inc.
- Modality Solutions
- NMDP BioTherapies
- Nordic Cold Chain Solutions
- Polar Express Transportation
- sedApta s.r.l.
- Thermo Fisher Scientific Inc.
- TrakCel
- Yourway
- YUSEN LOGISTICS
- AbbVie
- Abeona Therapeutics Inc.
- AD Ports Group
- ADIO
- AGC Biologics
- Almac Clinical Services
- Alnylam Pharmaceuticals
- Aramco
- Arsenal Biosciences
- AstraZeneca
- Atsena Therapeutics
- Autolus Therapeutics plc
- Avery Dennison
- Bayer AG
- Be The Match Biotherapies
- Biocad
- BioNTech SE
- bluebird bio, Inc.
- Bristol Myers Squibb
- Cartherics Pty Ltd
- Celgene Corporation
- Cell and Gene Therapy Catapult
- Cellbox Solutions GmbH
- Cellectis
- Cellply Srl
- Celltrion
- Charles River Laboratories International, Inc.
- CRISPR Therapeutics
- CryoPDP
- CSL Behring LLC
- Eli Lilly and Company
- Elixia
- Enzyvant Therapeutics GmbH
- Etihad Airways
- Eurofins Biopharma
- Exeltainer
- Ferring Pharmaceuticals A/S
- Frigo-Trans
- Gaelic Laboratories
- GeneOne Life Science Inc.
- Genprex, Inc.
- Gilead
- Global Cold Chain Solutions (GCCS)
- GSK
- Hupan Pharmaceutical
- Inception Fertility
- Indian Institute of Technology (IIT) Bombay
- Innovent Biologics Inc.
- Iovance Biotherapeutics
- IQVIA Canada
- Janssen Biotech, Inc.
- Jimma Pharmaceuticals Supply Agency
- Juno Therapeutics, Inc.
- Kite Pharma, Inc.
- Krystal Biotech
- Lakeside Holding Limited
- Lichtsteiner Foundation
- Life Couriers
- LifeX Ventures
- LOGISTEED, Ltd.
- Longfeng Medical Logistics
- Lonza
- Mesoblast Ltd.
- MilliporeSigma
- Miltenyi Biotec
- Minaris Regenerative Medicine Co., Ltd.
- MNX
- Nano Logistics
- Naql Masr
- National Resilience Inc.
- Neste
- Neurotech Pharmaceuticals
- NIPRO CORPORATION
- Novartis
- Novartis Gene Therapies, Inc.
- Novartis Pharmaceuticals Corporation
- Novo Holdings
- Novo Nordisk
- NovoPath
- OmniaBio
- OrbusNeich Medical Group Holdings Limited
- Orchard Therapeutics
- Orion Corporation
- Overhaul
- Owen Mumford
- Oxford Seed Fund
- PanTHERA CryoSolutions
- PBL
- Pelican BioThermal
- Pfizer
- PharmaLex Holding GmbH
- Polar Speed
- Prologis
- ProPharma
- Public Health Expertise (PHE)
- RapidShyp
- Rare Cancer Research Group
- RareCan
- Retina Consultants of America (RCA)
- Reverse Logistics
- Roche
- Samsung Biologics
- Sanofi
- Sarepta Therapeutics, Inc.
- SCG Cell Therapy Pte Ltd (SCG)
- Scintila S.R.O
- Sensitech
- Sinopharm Group Hubei
- SK Pharmteco
- Sonoco ThermoSafe
- Spark Therapeutics, Inc.
- Stratatech Corporation
- Sure Chill
- Syneos Health
- Taikoo Motors
- Tech4med
- The Binding Site Group
- TiCARos Co Ltd.
- TMRW Life Sciences
- TreeFrog Therapeutics
- Umoja Biopharma
- UniQure
- UniSafe
- UPS Healthcare Precision Logistics
- Vertex
- Verve Ventures
- Vetter
- VGXI, Inc.
- Viralgen
- Vitesco Technologies
- W.A. de Vigier Foundation
- Zuellig Pharma
- Zühlke Ventures
- Agência Nacional de Vigilância Sanitária (ANVISA)
- American Cancer Society
- Argentina government
- Berlin Institute of Health
- BioIndustry Association
- Bioprocessing Technology Institute (BTI)
- Caring Cross
- CCRM Australia
- Centers for Medicare and Medicaid Services (CMS)
- Centre for Biomanufacturing and Industrialisation Development Centre (CBIDC)
- Centre of Excellence for Independent Validators (CEIV)
- City of Hope
- Department of Health, Abu Dhabi (DoH)
- Fred Hutchinson Cancer Center
- Institut Curie
- Institut Pasteur
- International Air Transport Association (IATA)
- Kansai III Medical Distribution Center
- Karolinska Institutet
- King's College London
- MD Anderson Cancer Center
- Moffitt Cancer Center
- National Health Service (NHS)
- National Institute for Health and Care Excellence (NICE)
- National RNA Technology Institute (NATi)
- NCBI
- Newcastle University
- Novo Nordisk Foundation Cellerator
- Pan American Health Organization (PAHO)
- Paris-Saclay Cancer Cluster (PSCC)
- Riders for Health
- San Raffaele Telethon Institute for Gene Therapy
- Stanford University
- Thai Red Cross Society
- U.S. FDA
- University College London
- University of Oxford
- University of Pennsylvania
- World Bank
- World Health Organization (WHO)
- Yokohama Technical Center
- Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine)
